openPR Logo
Press release

Lawsuit filed for Investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC)

01-07-2022 07:23 PM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares.

A lawsuit was filed on behalf of investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares.

An investor in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) filed a lawsuit over alleged Securities Laws violations by Revance Therapeutics, Inc.

Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and for certain investors are short and strict deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Newark, CA based Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally.

On August 5, 2021, Revance Therapeutics, Inc. reported its second quarter financial results. In the announcement Revance Therapeutics, Inc. said that “Consistent with the company’s previous disclosure on the status of the pre-approval inspection, the FDA initiated the inspection of the company’s manufacturing facility in June 2021. Revance continues to anticipate receiving approval for DaxibotulinumtoxinA for Injection in 2021 and is actively building inventory and preparing for commercial launch.”

On October 12, 2021, Revance Therapeutics, Inc. issued a statement saying that it “continues to anticipate FDA approval of daxibotulinumtoxinA for injection for the treatment of glabellar lines in 2021”.

Then , on October 15, 2021, Revance Therapeutics, Inc. disclosed that the FDA could not approve the Biologics License Application (BLA) for DaxibotulinumtoxinA for Injection in its present form, citing deficiencies related to an inspection of Revance's manufacturing facility.

Shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) declined from $30.00 per share on September 27, 2021, to $13.01 per share on October 18, 2021.

The plaintiff claims that between November 25, 2019 and October 11, 2021, the Defendants made false and/or misleading statements and/or failed to disclose that quality control deficiencies existed at the Company’s manufacturing facility for DAXI, that the foregoing deficiencies decreased the likelihood that the FDA would approve the DAXI BLA in its current form, that accordingly, it was unlikely that the DAXI BLA would obtain FDA approval within the timeframe the Company had represented to investors, and that as a result, the Company’s public statements were materially false and misleading at all relevant times.

Those who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and should contact the Shareholders Foundation.

Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) here

News-ID: 2521010 • Views:

More Releases from Shareholders Foundation

Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR) over possible Violations of Securities Laws
Investigation announced for Investors in shares of Lifecore Biomedical, Inc. (NA …
An investigation was announced for investors of Lifecore Biomedical, Inc. (NASDAQ: LFCR) shares over potential securities laws violations by Lifecore Biomedical, Inc. Investors who purchased shares of Lifecore Biomedical, Inc. (NASDAQ: LFCR), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Lifecore Biomedical, Inc. regarding its business, its prospects and
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: DBI) over potential Wrongdoing by certain directors
Investigation announced for Investors in shares of Designer Brands Inc. (NYSE: D …
An investigation was announced over potential breaches of fiduciary duties by certain officers and directors at Designer Brands Inc. Investors who purchased shares of Designer Brands Inc. (NYSE: DBI) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Designer Brands Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Columbus,
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) should contact the Shareholders Foundation
Lawsuit Alert: Investors who lost money with shares of Innoviz Technologies Ltd. …
An investor, who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ), filed a lawsuit over alleged violations of Federal Securities Laws by Innoviz Technologies Ltd. in connection with certain allegedly false and misleading statements. Investors who purchased shares of Innoviz Technologies Ltd. (NASDAQ: INVZ) have certain options and for certain investors are short and strict deadlines running. Deadline: May 14, 2024. NASDAQ: INVZ investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NASDAQ: IRBT)
Lawsuit filed for Investors who lost money with shares of iRobot Corporation (NA …
An investor, who purchased shares of iRobot Corporation (NASDAQ: IRBT), filed a lawsuit over alleged violations of Federal Securities Laws by iRobot Corporation in connection with certain allegedly false and misleading statements. Investors who purchased shares of iRobot Corporation (NASDAQ: IRBT) have certain options and for certain investors are short and strict deadlines running. Deadline: May 7, 2024. NASDAQ: IRBT investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858)

All 5 Releases


More Releases for Revance

Investigation announced for Investors in Revance Therapeutics, Inc. (NASDAQ: RVN …
An investigation was announced for long-term investors in shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) concerning potential breaches of fiduciary duties by certain directors and officers of Revance Therapeutics, Inc. Investors who are current long term investors in Revance Therapeutics, Inc. (NASDAQ: RVNC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term
Deadline on Feb. 8th coming up in Lawsuit for INvestros in Revance Therapeutics, …
A deadline is coming up on February 8, 2022 in the lawsuit filed for certain investors of Revance Therapeutics, Inc. (NASDAQ: RVNC) over alleged securities laws violations by Revance Therapeutics, Inc. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC) have certain options and there are strict and short deadlines running. Deadline: February 8, 2022. NASDAQ: RVNC stockholders should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -
Investigation for Investors in NASDAQ: RVNC shares over possible Wrongdoing at R …
Certain directors of Revance Therapeutics, Inc. are under investigation over potential breaches of fiduciary duties. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm concerns whether certain Revance Therapeutics, Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders. Newark, CA based Revance Therapeutics,
Palmer Hyperhidrosis Treatment Market Research Report (2021-2027): Key Trends an …
Hyperhidrosis is a disorder that results in excessive sweating of palms, soles, or underarms. Palmer hyperhidrosis is excessive and uncontrollable hand sweating and is the most common type of hyperhidrosis. The sweating may range from mild to severe. Market Snapshot A recently published report by QY Research, titled “Global Palmer Hyperhidrosis Treatment Market Size, Status and Forecast 2022” gives an overview of the overall Palmer Hyperhidrosis Treatment market. This section
Investigation announced for Investors in shares of Revance Therapeutics, Inc. (N …
An investigation was announced over potential securities laws violations by Revance Therapeutics, Inc. in connection with certain financial statements. Investors who purchased shares of Revance Therapeutics, Inc. (NASDAQ: RVNC), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on whether a series of statements by Revance Therapeutics, Inc. regarding its business, its prospects and its operations were
Cervical Dystonia Pipeline 2020-2022| Revance Therapeutics, Inc., Syneos Health, …
The Global Cervical Dystonia Pipeline Insights 2020-2022: The research study has been prepared with the use of in-depth qualitative and quantitative analyses of the global Cervical Dystonia Market. The report offers complete and intelligent analysis of the competition, segmentation, dynamics, and geographical advancement of the Global Cervical Dystonia Market. It takes into account the CAGR, value, volume, revenue, production, consumption, sales, Manufacturing cost, prices, and other key factors related to the